• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

HBME-1与半乳糖凝集素-3免疫组织化学及BRAF V600E突变在甲状腺乳头状癌诊断中的联合应用

The Combined Utility of HBME-1 and Galectin-3 Immunohistochemistry and BRAF V600E Mutations in the Diagnosis of Papillary Thyroid Carcinoma.

作者信息

Ramkumar Subramaniam, Sivanandham Shanthakumari

机构信息

Pathology, Woodland Hospital, Shillong, IND.

Pathology, PSG Institute of Medical Sciences & Research, Coimbatore, IND.

出版信息

Cureus. 2021 Dec 10;13(12):e20339. doi: 10.7759/cureus.20339. eCollection 2021 Dec.

DOI:10.7759/cureus.20339
PMID:34934597
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8668044/
Abstract

Newer diagnostic modalities have revolutionized the pathologist's approach to diagnosing thyroid malignancies. Molecular characterization of these malignancies has helped circumvent common morphologic diagnostic difficulties by integrating their genotypic, phenotypic, and immunohistochemical features. V600E mutation has been characterized as highly specific for thyroid carcinoma, especially papillary thyroid carcinoma (PTC); human bone marrow endothelial marker-1 (HBME-1) and galectin-3 are also such markers that are highly specific for PTC. We propose to study HBME-1 and galectin-3 expression and V600E mutation in thyroid neoplasms and do a comparative analysis to determine whether there is a correlation between V600E expression and that of HBME-1 and galectin-3. We further propose to analyze the individual and combined diagnosed utility of the above-mentioned ancillary diagnostic techniques.

摘要

更新的诊断方法彻底改变了病理学家诊断甲状腺恶性肿瘤的方式。通过整合这些恶性肿瘤的基因型、表型和免疫组化特征，对其进行分子特征分析有助于规避常见的形态学诊断难题。V600E突变已被确定为对甲状腺癌具有高度特异性，尤其是对乳头状甲状腺癌（PTC）；人骨髓内皮标志物-1（HBME-1）和半乳糖凝集素-3也是对PTC具有高度特异性的标志物。我们建议研究甲状腺肿瘤中HBME-1和半乳糖凝集素-3的表达以及V600E突变，并进行比较分析，以确定V600E表达与HBME-1和半乳糖凝集素-3的表达之间是否存在相关性。我们还建议分析上述辅助诊断技术的个体诊断效用和联合诊断效用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/f61c611967ad/cureus-0013-00000020339-i08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/df7ac1d74a32/cureus-0013-00000020339-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/5cf30004955d/cureus-0013-00000020339-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/2d0cefafa55e/cureus-0013-00000020339-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/9797f79336d9/cureus-0013-00000020339-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/b39ff215d7ba/cureus-0013-00000020339-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/e0a6388bac10/cureus-0013-00000020339-i06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/e8e19570d7f8/cureus-0013-00000020339-i07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/f61c611967ad/cureus-0013-00000020339-i08.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/df7ac1d74a32/cureus-0013-00000020339-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/5cf30004955d/cureus-0013-00000020339-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/2d0cefafa55e/cureus-0013-00000020339-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/9797f79336d9/cureus-0013-00000020339-i04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/b39ff215d7ba/cureus-0013-00000020339-i05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/e0a6388bac10/cureus-0013-00000020339-i06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/e8e19570d7f8/cureus-0013-00000020339-i07.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99c7/8668044/f61c611967ad/cureus-0013-00000020339-i08.jpg

相似文献

1
The Combined Utility of HBME-1 and Galectin-3 Immunohistochemistry and BRAF V600E Mutations in the Diagnosis of Papillary Thyroid Carcinoma.HBME-1与半乳糖凝集素-3免疫组织化学及BRAF V600E突变在甲状腺乳头状癌诊断中的联合应用
Cureus. 2021 Dec 10;13(12):e20339. doi: 10.7759/cureus.20339. eCollection 2021 Dec.
2
Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.TROP-2表达在甲状腺乳头状癌中的诊断价值及其与HBME-1、半乳糖凝集素-3和细胞角蛋白19的比较
Pol J Pathol. 2017;68(1):1-10. doi: 10.5114/pjp.2017.67610.
3
Immunohistochemical expression of HBME-1 and galectin-3 in the differential diagnosis of follicular-derived thyroid nodules.HBME-1和半乳糖凝集素-3的免疫组化表达在滤泡性甲状腺结节鉴别诊断中的应用
Pathol Res Pract. 2014 Dec;210(12):971-8. doi: 10.1016/j.prp.2014.06.010. Epub 2014 Jun 27.
4
Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts.乳头状癌的滤泡变体：组织学诊断的可重复性以及HBME-1免疫组化和BRAF突变分析作为诊断辅助手段的效用
Appl Immunohistochem Mol Morphol. 2010 May;18(3):231-5. doi: 10.1097/PAI.0b013e3181c61cdd.
5
Immunohistochemical analysis of thyroid follicular neoplasms and BRAF mutation correlation.甲状腺滤泡性肿瘤的免疫组织化学分析及BRAF突变相关性
Indian J Cancer. 2014 Jan-Mar;51(1):63-8. doi: 10.4103/0019-509X.134648.
6
Atypical thyroid nodules express both HBME-1 and Galectin-3, two phenotypic markers of papillary thyroid carcinoma.非典型甲状腺结节同时表达HBME-1和Galectin-3，这是甲状腺乳头状癌的两种表型标志物。
J Exp Clin Cancer Res. 2007 Jun;26(2):221-7.
7
Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.联合甲状腺过氧化物酶、半乳糖凝集素-3、CK19 和 HBME-1 的免疫组化在甲状腺肿瘤鉴别诊断中的应用。
APMIS. 2012 May;120(5):368-79. doi: 10.1111/j.1600-0463.2011.02842.x. Epub 2011 Nov 19.
8
Expression of HBME-1 and CD56 in follicular variant of papillary carcinoma in children: An immunohistochemical study and their diagnostic utility.HBME-1 和 CD56 在儿童滤泡型甲状腺乳头状癌中的表达：免疫组织化学研究及其诊断价值。
Pathol Res Pract. 2019 May;215(5):880-884. doi: 10.1016/j.prp.2019.01.031. Epub 2019 Jan 28.
9
Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.甲状腺乳头状癌中BRAFV600E突变、BRAF V600E免疫组化及BRAF RNA原位杂交的临床病理相关性
Pathol Res Pract. 2015 Feb;211(2):162-70. doi: 10.1016/j.prp.2014.10.005. Epub 2014 Oct 27.
10
Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity?免疫组化标志物联合染色在甲状腺乳头状癌诊断中的应用：敏感性或特异性的提高？
J Int Med Res. 2013 Aug;41(4):975-83. doi: 10.1177/0300060513490617. Epub 2013 Jul 15.

引用本文的文献

1
FHL1: A novel diagnostic marker for papillary thyroid carcinoma.FHL1：甲状腺乳头状癌的新型诊断标志物。
Pathol Int. 2024 Sep;74(9):520-529. doi: 10.1111/pin.13467. Epub 2024 Aug 9.
2
Immunohistochemistry in the pathologic diagnosis and management of thyroid neoplasms.免疫组织化学在甲状腺肿瘤的病理诊断和治疗中的应用。
Front Endocrinol (Lausanne). 2023 May 31;14:1198099. doi: 10.3389/fendo.2023.1198099. eCollection 2023.
3
Follicular Growth Pattern Disease on Thyroid Fine-needle Aspiration Biopsy.甲状腺细针抽吸活检中的滤泡生长模式疾病。

本文引用的文献

1
Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma.CK19、半乳糖凝集素 -3、CD56、甲状腺过氧化物酶（TPO）及Ki67表达和BRAF突变在甲状腺乳头状癌中的诊断意义
Oncol Lett. 2018 Apr;15(4):4269-4277. doi: 10.3892/ol.2018.7873. Epub 2018 Jan 26.
2
The significance of Delphian lymph node in papillary thyroid cancer.Delphian淋巴结在甲状腺乳头状癌中的意义。
Asia Pac J Clin Oncol. 2017 Oct;13(5):e389-e393. doi: 10.1111/ajco.12480. Epub 2016 Mar 17.
3
Expression, clinical significance and mechanism of Slit2 in papillary thyroid cancer.
Balkan Med J. 2022 Jul 22;39(4):230-238. doi: 10.4274/balkanmedj.galenos.2022.2022-5-17. Epub 2022 Jun 20.
Slit2在甲状腺乳头状癌中的表达、临床意义及机制
Int J Oncol. 2016 May;48(5):2055-62. doi: 10.3892/ijo.2016.3412. Epub 2016 Mar 2.
4
Radiation exposure, young age, and female gender are associated with high prevalence of RET/PTC1 and RET/PTC3 in papillary thyroid cancer: a meta-analysis.辐射暴露、年轻以及女性性别与甲状腺乳头状癌中RET/PTC1和RET/PTC3的高患病率相关：一项荟萃分析。
Oncotarget. 2016 Mar 29;7(13):16716-30. doi: 10.18632/oncotarget.7574.
5
Histological variants and prognostic factors of papillary thyroid carcinoma at the Colombian Instituto Nacional de Cancerología, 2006-2012.2006 - 2012年哥伦比亚国立癌症研究所甲状腺乳头状癌的组织学变异及预后因素
Biomedica. 2015 Jul-Sep;35(3):429-36. doi: 10.7705/biomedica.v35i3.2598.
6
Relationship of body mass index with BRAF (V600E) mutation in papillary thyroid cancer.甲状腺乳头状癌中体重指数与BRAF（V600E）突变的关系。
Tumour Biol. 2016 Jun;37(6):8383-90. doi: 10.1007/s13277-015-4718-y. Epub 2016 Jan 5.
7
Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants.主要甲状腺乳头状癌变体的临床病理差异风险与预后
J Clin Endocrinol Metab. 2016 Jan;101(1):264-74. doi: 10.1210/jc.2015-2917. Epub 2015 Nov 3.
8
Variants of Papillary Thyroid Carcinoma: Multiple Faces of a Familiar Tumor.甲状腺乳头状癌的变体：一种常见肿瘤的多面性
Turk Patoloji Derg. 2015;31 Suppl 1:34-47. doi: 10.5146/tjpath.2015.01313.
9
Significance of CK19, TPO, and HBME-1 expression for diagnosis of papillary thyroid carcinoma.CK19、TPO及HBME-1表达对甲状腺乳头状癌诊断的意义
Int J Clin Exp Med. 2015 Mar 15;8(3):4369-74. eCollection 2015.
10
BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis.甲状腺微小乳头状癌中的BRAFV600E突变：一项荟萃分析。
Endocr Relat Cancer. 2015 Apr;22(2):159-68. doi: 10.1530/ERC-14-0531. Epub 2015 Jan 15.